2026-10-29 22:25:54 UTC#541444newconfirmednews
ABSI stock news
ABSI stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-12 19:04:00 UTC#448423newconfirmednews
JP Morgan raises Absci (ABSI) price target to $15.00 from $14.00, maintains Overweight rating
2026-10-12 11:26:15 UTC#446199newconfirmednews
HC Wainwright reiterates Buy rating on Absci, maintains $16 price target
2026-09-24 12:00:00 UTC#362163duplicateconfirmednews
Absci Corporation details Phase 2 trial design for endometriosis candidate ABS-201, targeting mid-2027 start
2026-09-24 12:00:00 UTC#362157newconfirmedpress release
Absci details Phase 2 STORYLINE trial for AI-designed endometriosis antibody ABS-201, targeting mid-2027 start
2026-09-23 10:59:49 UTC#354856newconfirmednews
Needham reiterates Buy rating on Absci Corporation, maintains $11 price target
tradingviewimportance 0.30trust 0.70Needham & Company, LLC +0.20Absci Corporation +0.30ABS-201 +0.30
2026-09-16 12:42:15 UTC#320704updateconfirmednews
Absci Corporation reports ABS-201 safety and progress, with pivotal data expected in December
2026-09-15 21:01:52 UTC#316955duplicateconfirmednews
Absci Corporation reiterates clinical pipeline progress and cash runway through 2028
2026-09-15 20:20:43 UTC#316667newconfirmednews
Absci Corporation advances ABS-201 clinical trials with Eli Lilly backing and cash runway through 2028
2026-09-08 10:57:00 UTC#280009newconfirmednews
BTIG raises Absci price target to $16.00 from $13.00
2026-08-12 12:51:10 UTC#165238duplicateconfirmednews
Absci Q2 2026 Update: $110.2M Cash Runway and Sabirnetug Phase II Readout Expected Late 2026
2026-08-12 11:03:25 UTC#164548updateconfirmednews
Absci Q2 2026: Reduced net loss, $110.2M cash runway into 2027; ALTITUDE-AD results due late-2026
2026-08-12 10:33:00 UTC#164305newconfirmednews
Needham maintains $11.00 price target on Absci Corporation (ABSI)
2026-08-11 23:48:04 UTC#162046updateconfirmednews
Absci targets ABS-201 proof of concept data in 2H 2026, extends cash runway to 2H 2028
2026-08-11 22:07:20 UTC#161670newconfirmednews
Absci reports positive Phase I interim data for ABS-201, highlights Eli Lilly partnership
2026-08-11 21:01:41 UTC#161327duplicateconfirmednews
Absci Corp reports Q2 adjusted loss of $0.21/share on $318K revenue, missing analyst expectations
2026-08-11 20:14:16 UTC#161140newconfirmednews
Absci Q2 revenue misses expectations as net loss widens; company closes $100M offering with Eli Lilly investment
2026-08-11 10:00:00 UTC#157688newconfirmednews
Upcoming US Earnings Calendar: Aramark, 908 Devices, and Others Scheduled for Week of August 11
dow_jonesimportance 0.40trust 0.90FactSet Research Systems Inc. 0Aramark 0908 Devices Inc. 0+2 entities
2026-08-10 11:44:42 UTC#152326updateconfirmednews
Absci Corporation Reports Q2 2026 Revenue Growth and Clinical Pipeline Expansion
2026-08-10 11:00:16 UTC#152080newforecastnews